Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus.
SLE
health-related quality of life
obesity
patient-reported outcomes
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
02 03 2021
02 03 2021
Historique:
received:
22
04
2020
revised:
03
06
2020
pubmed:
13
9
2020
medline:
29
6
2021
entrez:
12
9
2020
Statut:
ppublish
Résumé
Associations between BMI and health-related quality of life (HRQoL) in SLE have been implied, but data are scarce. We determined the impact of overweight and obesity on HRQoL in a large SLE population. We pooled cross-sectional baseline data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (N = 1684). HRQoL was evaluated using the 36-item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale and the European Quality of Life 5-dimension questionnaire (EQ-5D). Comparisons between BMI groups were conducted using the Mann-Whitney U test and adjustments using linear regression. Clinical relevance was determined by minimal clinically important differences (MCIDs). In total, 43.2% of the patients had BMI above normal and 17.4% were obese. Overweight and obese patients reported worse SF-36 physical component summary (PCS), physical functioning, role physical, bodily pain and FACIT-Fatigue scores than normal weight patients. Divergences were greater than corresponding MCIDs and more prominent with increasing BMI. Despite no clinically important difference in SF-36 mental component summary scores across BMI categories, patients experienced progressively diminished vitality and social functioning with increasing BMI. In linear regression analysis, BMI above normal and obesity were associated with worse PCS (standardized coefficient β = -0.10, P < 0.001 and β = -0.17, P < 0.001, respectively), FACIT-Fatigue (β = -0.11, P < 0.001 and β = -0.16, P < 0.001) and EQ-5D (β = -0.08, P = 0.001 and β = -0.12, P < 0.001) scores, independently of demographic and disease-related factors. The impact of BMI on the PCS and FACIT-Fatigue was more pronounced than that of SLE activity. Patients with SLE and BMI above normal experienced clinically important HRQoL diminutions in physical aspects, fatigue and social functioning. A survey of potential causality underlying this association is warranted.
Identifiants
pubmed: 32918459
pii: 5904410
doi: 10.1093/rheumatology/keaa453
pmc: PMC7937019
doi:
Banques de données
ClinicalTrials.gov
['NCT00424476', 'NCT00410384']
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260-1272Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
Scand J Rheumatol. 2017 Jul;46(4):273-280
pubmed: 27701937
N Engl J Med. 2005 Dec 15;353(24):2550-8
pubmed: 16354891
Med Care. 2005 Mar;43(3):203-20
pubmed: 15725977
Arthritis Rheum. 2008 Apr 15;59(4):458-64
pubmed: 18383420
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Psychosomatics. 2009 Sep-Oct;50(5):474-82
pubmed: 19855033
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Int J Rheum Dis. 2012 Jun;15(3):261-7
pubmed: 22212605
Qual Life Res. 2007 Dec;16(10):1595-603
pubmed: 17957495
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Health Qual Life Outcomes. 2017 Oct 10;15(1):197
pubmed: 29017494
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):665-72
pubmed: 22704691
Qual Life Res. 1999 Dec;8(8):687-91
pubmed: 10855342
J Rheumatol. 1997 Aug;24(8):1608-14
pubmed: 9263159
Patient Relat Outcome Meas. 2019 Jan 09;10:1-7
pubmed: 30666173
PLoS One. 2014 Jun 03;9(6):e98883
pubmed: 24892282
Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):221-33
pubmed: 24625040
Autoimmun Rev. 2017 Apr;16(4):343-351
pubmed: 28216072
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9
pubmed: 11124729
Arthritis Care Res (Hoboken). 2019 Jun;71(6):811-821
pubmed: 30055091
J Rheumatol. 1999 Jan;26(1):97-102
pubmed: 9918248
Scand J Rheumatol. 2012 Oct;41(5):383-90
pubmed: 22646821
Lupus. 2010 Dec;19(14):1606-13
pubmed: 20829309
Arthritis Rheum. 2005 Nov;52(11):3651-9
pubmed: 16258902
Scand J Rheumatol. 2015 May;44(3):206-10
pubmed: 25656604
Lupus. 2016 Apr;25(5):505-12
pubmed: 26635245
Spine J. 2007 Sep-Oct;7(5):541-6
pubmed: 17448732
Lancet. 2011 Feb 26;377(9767):721-31
pubmed: 21296403
BMC Immunol. 2017 Mar 28;18(1):17
pubmed: 28351341
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Lupus. 2019 Feb;28(2):163-173
pubmed: 30580659
Arthritis Rheum. 2011 Dec;63(12):3918-30
pubmed: 22127708
Arthritis Rheum. 2004 Jun 15;51(3):465-74
pubmed: 15188335
J Clin Epidemiol. 2003 May;56(5):395-407
pubmed: 12812812
Expert Rev Pharmacoecon Outcomes Res. 2005 Jun;5(3):317-26
pubmed: 19807601
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Arthritis Rheum. 2009 Sep 15;61(9):1179-86
pubmed: 19714612
Lupus. 2015 Feb;24(2):191-7
pubmed: 25335488
Clin Rheumatol. 2010 Dec;29(12):1413-7
pubmed: 20437067
Ann Rheum Dis. 2014 May;73(5):838-44
pubmed: 23524886
Ann Rheum Dis. 2019 Jun;78(6):802-806
pubmed: 30992296